Helmy Eltoukhy is the co-Founder, Chairman and co-CEO of Guardant Health, Inc. After receiving his PhD, MS and BS degrees in electrical engineering from Stanford University, he joined the Stanford Genome Technology Center as a post-doctoral fellow in 2006 to work on low-cost DNA sequencing technologies. In 2007, he co-founded Avantome to commercialize semiconductor sequencing to help speed up the democratization of high throughput DNA sequencing which was acquired by Illumina in 2008. At Illumina, Eltoukhy was senior director of Advanced Technology Research, where he developed novel chemistries, hardware, and informatics for genetic analysis systems. In 2012, Eltoukhy co-founded Guardant Health with fellow electrical engineer and Stanford University alumnus Dr. AmirAli Talasaz. Eltoukhy was named to Fortune’s 40 under 40, and the San Francisco Business Times’ 40 under 40 in 2019. Eltoukhy was also named one of Time Magazine's 50 Most Influential People in Healthcare and was ranked #12 on The Healthcare Technology Report Top 50 Healthcare Technology CEO. He has served as an invited speaker or panelist at events including the World Economic Forum, The Business of Personalized Medicine Summit, and Fortune Brainstorm Health.